The ovarian hormones estradiol (E 2 ) and progesterone (P) facilitate rat lordosis behavior in part by regulating the expression of and signal transduction by adrenoceptors in the hypothalamus (HYP) and preoptic area (POA). The major adrenoceptor subtype mediating E 2 and P facilitation of lordosis is the ␣ 1 -adrenoceptor. In the present studies, we tested the hypotheses that (1) ␣ 1 -adrenoceptors in the HYP enhance lordosis responses by activating the nitric oxide (NO)-cGMP signaling pathway, and (2) coupling of ␣ 1 -adrenoceptors to this signal transduction pathway is hormone-dependent. Basal levels of cGMP were significantly higher in HYP and POA slices from animals treated with E 2 and P when compared with slices from ovariectomized controls or females treated with only E 2 or P. When slices of HYP and POA from ovariectomized female rats were incubated with norepinephrine or the selective ␣ 1 -adrenoceptor agonist phenylephrine, cGMP accumulation was observed only if slices had been derived from females treated with both E 2 and P before experimentation. Moreover, ␣ 1 -adrenoceptor stimulation of cGMP synthesis was blocked by an inhibitor of NO synthase, confirming that these receptors act by NO-mediated stimulation of soluble guanylyl cyclase. Behavioral studies demonstrated further that the cell-permeable cGMP analog 8-bromoadenosine-cGMP reverses the inhibitory effects of the ␣ 1 -adrenoceptor antagonist prazosin on lordosis behavior in E 2 -and P-treated female rats. Thus, the NO-cGMP pathway mediates the facilitatory effects of ␣ 1 -adrenoceptors on lordosis behavior in female rats, and previous exposure of the HYP and POA to both E 2 and P are required to link ␣ 1 -adrenoceptors to this pathway.
Norepinephrine (N E) neurotransmission in the hypothalamus (HYP) and preoptic area (POA) is a key player in estradiol (E 2 ) and progesterone (P) coordination of preovulatory gonadotropin secretion and reproductive behavior of female rodents (Kalra and Kalra, 1983; Etgen et al., 1992; Pfaff et al., 1994) . Ample evidence implicates ␣ 1 -adrenoceptors in these brain regions as the mediators of N E facilitation of gonadotropin secretion (Ramirez et al., 1984) and of lordosis, a major component of female reproductive behavior . Moreover, E 2 priming elevates ligand binding and mRNA levels of the ␣ 1B -adrenoceptor subtype in HYP-POA Karkanias et al., 1996) . The ␣ 1 -adrenoceptors activate phospholipase C to produce inositol-1,4,5-triphosphate (I P 3 ), which mobilizes intracellular calcium, and diacylglycerol, which activates protein kinase C Minneman, 1986, 1987) . The ␣ 1 -adrenoceptors also increase influx of extracellular calcium through calcium channels (Minneman, 1988) . In HYP and POA slices from E 2 -primed female rats, P attenuates ␣ 1 -adrenoceptor stimulation of I P 3 formation and abolishes ␣ 1 -adrenoceptor augmentation of adenylyl cyclase, a protein kinase C-mediated response (Petitti and Etgen, 1989 , 1990 Karkanias et al., 1995) . However, the signal transduction mechanisms mediating ␣ 1 -adrenoceptor facilitation of lordosis behavior are still unknown.
Nitric oxide (NO) is a diffusible messenger synthesized by NO synthase, a calcium-calmodulin-activated enzyme (Snyder and Bredt, 1991) . Because NO synthase is activated by elevation of intracellular calcium, the effects of ␣ 1 -adrenoceptors on reproductive function may be mediated by NO. Recently, NO was found to regulate the secretion of gonadotropin-releasing hormone (GnRH) both in vivo and in vitro (Bonavera et al., 1993; Moretto et al., 1993; Rettori et al., 1993 Rettori et al., , 1994 Mahachoklertwattana et al., 1994; Lopez et al., 1997) . NO appears to act in the POA to stimulate GnRH release by activating soluble guanylyl cyclase to synthesize cGMP (Brann et al., 1997; Pu et al., 1997 Pu et al., , 1998 . Manipulations of brain NO and cGMP levels also modulate lordosis behavior (Fernandez-Guasti et al., 1983; Mani et al., 1994; Chu et al., 1999) . Indeed, NO facilitates lordosis in hormone-treated females through activation of soluble guanylyl cyclase (Chu and Etgen, 1997; Chu et al., 1999) .
Interestingly, brain NO synthase expression and mRNA levels increase in POA and HYP after estrogen priming (Okamura et al., 1994a,b; Ceccatelli et al., 1996; Pu et al., 1998) . In addition, P increases guanylyl cyclase activity in some peripheral tissues (Vesely and Hill, 1980) . HYP levels of cGMP increase significantly on the evening of proestrus, a time characterized by high levels of P and behavioral receptivity in gonadally intact rats (Kimura et al., 1980) . Therefore, the present study tested the hypothesis that E 2 and P promote the linkage of HYP-POA ␣ 1 -adrenoceptors to the NO -cGM P pathway and that this signaling system mediates ␣ 1 -adrenoceptor facilitation of lordosis behavior. We measured the cGM P response to N E and an ␣ 1 -adrenergic agonist in HYP-POA slices of hormone-treated female rats. NO synthase inhibitors were used to examine the role of NO in N E-dependent cGM P accumulation. The ability of a cGMP analog to reverse the inhibition of lordosis behavior produced by ␣ 1 -adrenergic antagonists was also evaluated.
MATERIALS AND METHODS
Determination of cGMP levels in vitro. All animal experimentation was performed in accordance with National Institutes of Health guidelines and was approved by the Institutional Animal C are and Use Committee. Female Sprague Dawley rats weighing 150 -175 gm were purchased from Taconic Farms (Germantown, N Y) and maintained with food and water ad libitum. Animals were ovariectomized under Metofane (PitmanMoore, Mundelein, IL) anesthesia 1 d after arrival. Five or 6 d later, animals received the first of two daily injections of 2 g E 2 benzoate (EB) in 0.1 ml of peanut oil vehicle or 0.1 ml of oil (control) subcutaneously. P (200 g) in 0.1 ml of oil or oil vehicle was injected subcutaneously 42-44 hr after the first EB or vehicle injection. Four hours after P or vehicle administration, animals were killed by decapitation. This time course of hormone treatment was chosen because ovariectomized animals reliably exhibit lordosis behavior under this regimen of hormone injections Chu et al., 1999) . All animals were killed at the same time of day (10:00 A.M. to 11:00 A.M.) to control for reported diurnal rhythms in cGM P in the female rat POA (Pu et al., 1998) .
The brain was removed, a block containing the entire HYP-POA was dissected, and eight 400 m slices were made with a McI lwain tissue chopper. Individual slices were collected in culture wells and preincubated for 90 min at 33-35°C in buffer containing (in mM): 26 NaHC O 3 , 11 glucose, 120 NaC l, 2 KC l, 1.18 K H 2 PO 4 , 1.19 MgSO 4 , and 2 CaCl 2 . The 90 min preincubation period allows cGM P levels in the slices to return to baseline from the elevated state caused by decapitation. An inhibitor of phosphodiesterase, 1 mM 1,3-isobutyl-1-methylxanthine, was also included in the medium. At the end of the 90 min preincubation, N E (100 M) or the ␣ 1 -adrenergic agonist phenylephrine (10 M) was applied for 20 min. In some experiments, the NO synthase inhibitors N G -nitro-L-arginine methyl ester (NAM E) (100 M) or N G -nitro-arginine (NO-ARG) (300 M) or the ␣ 1 -adrenergic antagonist prazosin (10 M) was applied for 20 min before N E or phenylephrine.
Tissue slices were then placed in 5% trichloroacetic acid for deproteinization. C yclic nucleotides and protein were separated by homogenization and centrif ugation. Trichloroacetic acid was later removed by ether extraction. Samples containing cyclic nucleotides were then lyophilized and assayed for cGM P content by radioimmunoassay (Amersham, Arlington Heights, IL). This assay system provides a sensitive and specific assay for cGM P (detection limit, 0.04 pmol). Protein contents of the tissue slices were determined by the L owry method (L owry et al., 1951) , and data are expressed as picomoles of cGM P per milligram of protein.
Distribution of basal cGMP levels along the anteroposterior a xis of the POA-H Y P. We consistently observe an uneven distribution of cAM P along the anteroposterior axis of POA-HYP (N. Petitti and A. M. Etgen, unpublished observations) . Therefore, we analyzed the basal content of cGM P according to localization along the anteroposterior axis of POA-HYP. A significant effect of location was found (F (3,42) ϭ 4.99; p Ͻ 0.05; n ϭ 15). The most posterior quarter of the POA-HYP block had significantly lower cGM P levels (1.42 Ϯ 0.26 pmol /mg protein) than the most anterior quarter (2.02 Ϯ 0.29 pmol /mg protein). To avoid any possible masking effect caused by this uneven distribution, every two consecutive slices were used as a pair; one slice was treated with drug or vehicle, and one slice was untreated (basal cGM P). The order of treatment in a pair alternated from day to day of the same experiment. Likewise, drug treatment was randomly assigned to the four pairs of slices along the anteroposterior axis. We observed no effects of anteroposterior location on responses to any drugs. The ratio of cGM P levels from the two slices in a pair (treated /untreated) is usually presented in Results to provide a more informative within-subject comparison of drug effects.
Stereota xic surger y and behavior testing. Female Sprague Dawley rats (175-200 gm) were maintained on a reverse14/10 hr light /dark cycle, with lights off at 11:00 A.M. The day after arrival, animals were anesthetized with xylazine (4 mg / kg) and ketamine (80 mg / kg), placed into a stereotaxic apparatus, and secured with ear bars and a nose piece set at ϩ5.0 mm. A 26 gauge guide cannula (Plastics One, Roanoke, VA) was implanted into the third ventricle using coordinates from the atlas of Pellegrino et al. (1979) : ϩ 0.2 mm posterior, 0 mm lateral, and ϩ 9 mm ventral with respect to bregma. Bilateral ovariectomy was done at the same time as stereotaxic surgery. Reproductive behavior testing was performed 1 week after surgery. Rats received two subcutaneous injections of 2 g of EB 24 and 48 hr before behavioral testing. Some animals also received 200 g of P 4 hr before testing. The hydrolysis-resistant cGM P analog, 8-bromoadenosine-cGM P (8-br-cGM P) (1 M), was inf used into the third ventricle in a volume of 2 l 4 hr before behavior testing. The dose and timing of 8-br-cGM P inf usion was based on previous experiments (Chu et al., 1999) showing that 8-br-cGM P can stimulate lordosis responding when inf used into the third ventricle of EB-primed rats.
For reproductive behavior testing, experienced stimulus male rats were placed in 20 gallon glass arenas and allowed to adapt for 10 min. Females were then placed in the arenas with a male until they received 10 mounts with pelvic thrusting. A lordosis quotient (L Q ϭ number of lordosis responses/number of mounts ϫ 100) was used as a measure of behavioral receptivity. The quality of each lordosis was also scored on a scale of 0 -3 (0, no lordosis; 1, shallow lordosis; 2, definite dorsiflexion of the spine; and 3, exaggerated lordosis). In addition, the presence or absence of proceptive (soliciting) behaviors was recorded. Animals were tested three times at hourly intervals, with the first test at 4 hr after drug or saline inf usion into the third ventricle. To determine whether any treatments altered the general activity level of animals, two components of open field activity were measured in a 5 min test immediately after the first lordosis test. The number of lines crossed on a grid composed of 10 5 ϫ 5 inch squares, and the number of rearing events, defined as the number of times the rat lifted both forepaws off the cage floor, were recorded.
Animals were anesthetized with 40 mg of ketamine and decapitated immediately after the final test for lordosis. The brain was removed, frozen in isopentane for 1 min at approximately Ϫ35°C, and stored at Ϫ70°C. Frozen brains were sectioned (40 m) in the transverse plane on a cryostat microtome. Every fourth section was saved throughout the extent of the cannula tracks. Anatomical verification of the cannula placement was made according to the atlas of Pellegrino et al. (1979) .
Materials and drug preparation. NAM E and NOARG were purchased from Research Biochemicals (Natick, M A). EB and P were purchased from Steraloids, Inc. (Wilton, N H). Prazosin, N E, and phenylephrine were purchased from Sigma (St. L ouis, MO), and 8-br-cGM P was purchased from C albiochem (La Jolla, CA). Phenylephrine, NAM E, and NOARG were prepared in distilled water. Prazosin was prepared in saline containing 25% propylene glycol. N E was prepared in 0.01 N HC l, and 8-br-cGM P was prepared in sterile saline.
Statistical anal ysis. Levels of cGM P or ratios of cGM P levels of slices in a pair were analyzed with either one-way or two-way ANOVA as appropriate, with hormone as the between-subject factor and drug as the within-subject factor, followed by T ukey post hoc tests. Behavioral data were analyzed using two-way ANOVA with drug as the between-subject factor and the test number as the within-subject factor, followed by T ukey post hoc tests. Differences were considered significant if p Ͻ 0.05.
RESULTS

Basal cGMP levels in HYP-POA slices of EB-and P-primed animals
Because cGMP levels are reported to be highest on the afternoon of proestrus in gonadally intact female rats (Kimura et al., 1980) and because we hypothesize that E 2 and P enhance the activity of NO-cGMP pathway, we first examined basal cGMP content in the POA-HYP slices obtained from ovariectomized animals treated with different hormones. The average cGMP content of all slices from the same rat was used to calculate the basal cGMP levels for each animal. There is a significant effect of hormone treatment on basal cGMP (F (3,18) ϭ 14.50; p Ͻ 0.05; n ϭ 5-7). Post hoc analysis indicated that slices from EB plus P-treated animals have significantly higher levels of cGMP than slices from control, EB-or P-treated animals (Fig. 1) .
NE and phenylephrine stimulate cGMP accumulation only in EB plus P-treated animals
Because we hypothesize that N E, through ␣ 1 -adrenoceptors, activates cGM P production in a hormone-dependent manner, we tested the effects of N E on cGM P accumulation in slices from rats killed after different hormone treatments. Phenylephrine, an ␣ 1 -adrenergic agonist, was also used to determine the role of ␣ 1 -adrenoceptors in regulation of cGM P synthesis. Ratios of cGMP levels from two consecutive slices (one treated with NE, phenylephrine, or vehicle; one untreated) in a pair are shown in Figure 2 . ANOVA indicated that there was a significant main effect of hormone treatment (F (3, 36) ϭ 4.39; p Ͻ 0.05; n ϭ 5-7); the main effect of drug and the drug ϫ hormone treatment interaction were not significant ( p Ͼ 0.10). Figure 2 demonstrates that there is a significant increase of cGM P in response to 100 M NE and 10 M phenylephrine only in slices from EB plus P-treated females (Tukey test; p Ͻ 0.05). In the other hormone groups, neither NE nor phenylephrine significantly increased cGMP accumulation in POA-HYP slices. In addition, there was no difference between the magnitude of NE and phenylephrine stimulation, with both drugs increasing cGMP to ϳ150% of basal levels, in the EB plus P slices. These results suggest that ␣ 1 -adrenoceptors may mediate the effects of NE and phenylephrine on cGMP levels in EB plus P-primed animals.
However, phenylephrine is known to act on the NE transporter to enhance NE release (Ari et al., 1989) . Thus, phenylephrine effects might be mediated through NE acting at non-␣ 1 -adrenoceptors. Hence, the ␣ 1 -adrenergic antagonist prazosin (10 M) was used to examine the role of ␣ 1 -adrenoceptors in phenylephrine-induced cGMP increases. The slices used in this experiment were from EB plus P-primed rats, because NE and phenylephrine stimulate cGMP production only in animals with EB plus P treatment. Figure 3 demonstrates that prazosin blocks phenylephrine stimulation of cGMP synthesis (F (3,18) ϭ 7.14; p Ͻ 0.05; n ϭ 7). Again, responses to NE and phenylephrine are not different. Therefore, ␣ 1 -adrenoceptors mediate the effects of phenylephrine on cGMP accumulation.
NO mediates NE stimulation of cGMP formation in HYP-POA Next, we investigated the role of NO in ␣ 1 -adrenoceptor activation of cGMP synthesis. We hypothesize that, in EB plus P-exposed slices, ␣ 1 -adrenoceptor activation increases intracellular calcium via both the IP 3 pathway and influx of extracellular calcium. NO synthase is thus activated to enhance the production of cGMP by soluble guanylyl cyclase. Two NO synthase inhibitors were used to test this hypothesis: NAME and NOARG. Both NAME and NOARG blocked NE-induced cGMP production (Fig. 4) (F (3, 21) ϭ 6.23; p Ͻ 0.05; n ϭ 8). Furthermore, the two drugs markedly reduced the basal content of cGMP. In fact, the cGMP levels in some drug-treated slices were under the detection limit of the assay. Figure 1 . Priming with EB plus P increases basal cGM P levels in HYP-POA slices of ovariectomized female rats. Animals were injected subcutaneously with 2 g of EB or 0.1 ml of vehicle (oil) at 24 and 48 hr before being killed. Some of the oil-and EB-treated rats were also injected subcutaneously with 200 g of P 4 hr before being killed. The data are shown as mean Ϯ SEM (n ϭ 5-7). *p Ͻ 0.05 versus oil, EB, and P; Tukey test. Figure 2 . NE and phenylephrine (PHE) stimulate cGM P production only in EB plus P-treated HYP-POA slices. Hormone treatments were the same as described in Figure 1 . Either 100 M N E or 10 M phenylephrine was administered in vitro for 20 min. The ratio was calculated as the cGMP level in a drug-treated slice/the cGM P level in an adjacent, vehicle-treated slice. The data are shown as mean Ϯ SEM (n ϭ 5-7). *p Ͻ 0.05 versus oil, EB, and P; T ukey test. Figure 3 . Prazosin (Praz) blocks the stimulatory effect of phenylephrine (PHE) on cGM P production in HYP-POA slices from EB plus P-treated animals. N E (100 M), phenylephrine (10 M), or vehicle (0.01N HCl) was administered in vitro for 20 min after 20 min preincubation with prazosin or vehicle (0.25% propylene glycol). Control slices were exposed to both vehicles. Ratios were calculated as described in Figure 2 . The data are shown as mean Ϯ SEM (n ϭ 7). *p Ͻ 0.05 versus control; Tukey test.
8-Br-cGMP reverses prazosin inhibition of lordosis behavior
To test the hypothesis that ␣ 1 -adrenoceptor activation of the NO-cGM P pathway is behaviorally relevant, we used a cellpermeable hydrolysis-resistant cGM P analog, 8-br-cGMP. It is well known that systemic (Vincent and Etgen, 1993) or intrahypothalamic (Etgen, 1990 ) administration of the ␣ 1 -adrenergic antagonist prazosin inhibits lordosis behavior in E 2 plus P-primed rats. Conversely, 8-br-cGM P and other cGMP derivatives potentiate lordosis behavior (Fernandez-Guasti et al., 1983; Chu et al., 1999) . To reconfirm the facilitatory effects of 8-brcGMP on lordosis in the present experiment, we first infused either 1 M 8-br-cGM P or saline in a volume of 2 l into the third ventricle of ovariectomized EB-primed females that did not receive P. It is easier to detect facilitatory effects of drugs such as 8-br-cGM P using low priming doses of EB, because female rats rarely exhibit lordosis behavior under these circumstances without addition of P. Four hours after 8-br-cGM P inf usion, animals were tested for lordosis behavior and locomotor activities (rearing and grid crossing). Figure 5A shows that animals treated with 8-br-cGM P have threefold higher L Q scores than control animals (F (1,18) ϭ 5.82; p Ͻ 0.05; n ϭ 3-5). Inf usion of 8-br-cGMP also significantly increases the quality of lordosis (data not shown).
A separate set of female rats implanted with a guide cannula into the third ventricle were primed with both EB and P to produce moderate-to-high levels of lordosis. The ␣ 1 -adrenoceptor antagonist prazosin, in a dose known to reliably inhibit lordosis behavior (0.5 mg / kg, i.p.) (Vincent and Etgen, 1993) , was given to all the animals 44 hr after the first EB injection. One hour later, 8-br-cGM P or saline was infused into the third ventricle concomitantly with subcutaneous injection of 200 g of P. Female rats usually show L Q values of ϳ75 with these doses of EB and P (Fig. 5B) (Chu and Etgen, 1997) . Figure  5B shows that prazosin reduces L Q scores to between 20 and 40 and that 8-br-cGM P reverses the inhibitory effects of prazosin on lordosis behavior (F (1,7) ϭ 91.5; p Ͻ 0.05; n ϭ 3). Similarly, 8-br-cGM P in the prazosin-injected animals also restores the quality of lordosis (data not shown). These data are consistent with the hypothesis that cGMP acts downstream from the ␣ 1 -adrenoceptor to facilitate lordosis behavior in EB plus P-treated rats. Tests for locomotion for both sets of rats indicated that prazosin and 8-br-cGMP do not change locomotor activities (data not shown).
DISCUSSION
To our knowledge, this is the first evidence that ovarian steroids promote the linkage of a G-protein-coupled receptor, the ␣ 1 -adrenoceptor, to a previously inactive signal transduction pathway. Moreover, the behavioral data demonstrate that the new signaling pathway (NO-cGMP) may mediate the facilitatory effects of NE on reproductive behavior. Reports from other laboratories suggest further that ovarian hormone-dependent, ␣ 1 -adrenergic facilitation of GnRH release in female rats may also involve NO (Canteros et al., 1995 (Canteros et al., , 1996 Kamat et al., 1995) . Our past studies demonstrated that treatment with behaviorally relevant doses of estrogen alone enhances ␣ 1 -adrenoceptor augmentation of cAMP formation, apparently by increased expres- Figure 4 . The NO synthase inhibitors NAM E and NOARG block cGMP production in slices from EB plus P-treated animals. NAM E (100 M ), NOARG (300 M), or vehicle (distilled water) was administered 20 min before stimulation with 100 M N E or vehicle (0.01N HC l) for 20 min. Control slices were exposed to both vehicles. Ratios were calculated as described previously. The data are shown as mean Ϯ SEM (n ϭ 8). *p Ͻ 0.05 versus control; #p Ͻ 0.05 versus control and N E; T ukey test. Figure 5 . Facilitation of lordosis behavior by 8-br-cGMP and 8-brcGM P reversal of prazosin inhibition of lordosis behavior. In A, 8-brcGM P (1 M) or saline was inf used into the third ventricle of rats primed only with EB for 44 hr; hourly behavior testing began 4 hr later. In B, EB-primed rats were injected with 0.5 mg / kg prazosin 1 hr before inf usion of 1 M 8-br-cGM P or saline into the third ventricle. P (200 g) was given subcutaneously to all the animals at the same time as 8-brcGM P or saline inf usion. (‚ indicates the mean L Q Ϯ SEM from animals receiving the same hormone priming without prazosin or 8-br-cGMP; n ϭ 13) (Chu and Etgen, 1997) . The data are shown as mean Ϯ SEM (n ϭ 3-5). p Ͻ 0.05 versus saline; T ukey test.
sion of ␣ 1B -adrenergic receptor binding sites and mRNA in the HYP-POA (Petitti and Etgen, 1990; Karkanias et al., 1996) . Interestingly, P treatment either in vivo Etgen, 1989, 1990) or in vitro abolishes ␣ 1 -adrenoceptor augmentation of cAM P accumulation in both HYP and POA slices, but only if animals were first exposed to E 2 . These changes in ␣ 1 -adrenoceptor signal transduction are not correlated with changes in the affinity or density of ␣ 1 -adrenoceptor binding sites Karkanias et al., 1995) . P treatment also attenuates N E-and phenylephrinestimulated I P 3 formation in hypothalamic slices from E 2 -treated females (Karkanias et al., 1995) . Thus, in female rats receiving hormone treatments that would result in high levels of lordosis behavior and in robust gonadotropin surges, we find marked changes in intracellular signaling by ␣ 1 -adrenoceptors, which are known to mediate N E facilitation of both lordosis behavior and GnRH release.
In the present study, we demonstrate that combined treatment with E 2 and P promotes ␣ 1 -adrenoceptor activation of cGMP synthesis in HYP-POA slices. In fact, N E and phenylephrine do not activate cGM P production in these brain regions if the slices are not prepared from animals exposed to both EB and P. The ability of NO synthase inhibitors to block N E stimulation of brain slice cGM P accumulation indicates that NO-activated soluble guanylyl cyclase is the source of N E-induced cGM P synthesis. These data are consistent with the hypothesis that ␣ 1 -adrenoceptors in the HYP-POA couple to the NO -cGMP second messenger system only after P administration to estrogenprimed animals. Moreover, when combined with our previous observations, the findings suggest that, after both E 2 and P treatment, the ratio of cAM P/cGM P produced by activation of ␣ 1 -adrenoceptors in the HYP-POA shifts in favor of cGMP. Hence, it is likely that activation of ␣ 1 -adrenoceptors in the HYP-POA of E 2 plus P-treated rats would result in greater activation of cGM P-dependent protein kinase and less activation of cAM P-dependent protein kinase. This change could have profound implications for the nature of cellular responses to endogenously released N E. For example, changes in the relative activities of cAM P-dependent protein kinase and cGMPdependent protein kinase alter cellular responses to phospholipase A 2 activation in smooth muscle (Murthy and Makhlouf, 1998) , modulate olfactory signal transduction (Zufall and LeiderZufall, 1998) , and influence the expression of long-term depression in hippocampal slices (Santschi et al., 1999) .
It is also interesting that combined treatment with EB and P increases basal cGM P levels in HYP-POA slices. This is a physiologically relevant finding because previous reports found that HYP levels of cGM P increase significantly on the evening of proestrus, a time characterized by high levels of E 2 and P in gonadally intact rats (K imura et al., 1980) . NO synthase expression increases with estrogen priming in the POA and ventromedial HYP, measured by NADPH-diaphorase staining and by immunocytochemistry and immunoblotting for the brain isoform (Okamura et al., 1994a,b; Rachman et al., 1996; Pu et al., 1998) . Thus, E 2 may promote activation of NO generation (and therefore cGM P accumulation) in part by elevating levels of the synthetic enzyme NO synthase. T wo early reports indicated that P alone increases guanylyl cyclase activity in skeletal, kidney, liver, and uterine tissues from guinea pigs and rats (Vesely, 1979; Vesely and Hill, 1980) . Perhaps these two mechanisms together account for the observation that both basal and ␣ 1 -adrenoceptorstimulated cGM P levels are significantly elevated in the HYP-POA only when both hormones are administered. Recent studies of muscarinic receptor coupling to the NO-cGMP pathway suggest that prolonged, agonist-induced elevations in NO-stimulated cGMP levels may be attributable to influx of extracellular calcium rather than release of intracellular calcium from storage pools (Wotta et al., 1998) . Therefore, it is interesting to speculate that the addition of P to E 2 -primed HYP-POA switches the preferred mode of ␣ 1 -adrenoceptor signal transduction from mobilization of intracellular calcium to influx of extracellular calcium.
We showed previously that cGMP, produced by NO activation of soluble guanylyl cyclase, facilitates lordosis behavior in hormone-treated female rats (Chu and Etgen, 1997; Chu et al., 1999) . Here, in the behavioral experiment, we report that 8-brcGMP reverses the inhibitory effects of the ␣ 1 -adrenergic antagonist prazosin on lordosis of EB plus P-primed female rats. Moreover, the ability of ␣ 1 -adrenoceptors to activate soluble guanylyl cyclase in the HYP-POA appears to be hormonedependent. Together, these results suggest that NO-stimulated cGMP production acts downstream of ␣ 1 -adrenoceptor activation to enhance lordosis responsiveness. Our behavioral data also support the hypothesis that the NO-cGMP pathway mediates NE facilitation of hormone-dependent lordosis behavior. The lordosis-relevant molecular targets of cGMP action in the HYP-POA are not known. However, an inhibitor of cGMP-dependent protein kinase, a major mediator of NO-induced cGMP action (El-Husseini et al., 1998) , and the P receptor antagonist RU 38486 both block cGMP facilitation of lordosis (Chu et al., 1999) .
NO has also been proposed to mediate the estrogen-dependent effects of ␣ 1 -adrenoceptors in the POA on the release of GnRH, the major neuropeptide controlling ovulation (Canteros et al., 1995 (Canteros et al., , 1996 Kamat et al., 1995) . In addition, NO mediates the stimulatory effects of glutamate (Mahachoklertwattana et al., 1994; Rettori et al., 1994) , leptin (Yu et al., 1997) , and oxytocin (Rettori et al., 1997) on GnRH secretion. These stimulatory effects of NO in the POA are believed to involve activation of soluble guanylyl cyclase, which leads to enhanced production of cGMP (Brann et al., 1997) . We demonstrated in our previous studies (Chu and Etgen, 1997; Chu et al., 1999) that the NOcGMP pathway, acting through cGMP-dependent protein kinase and the P receptor, is important in the regulation of lordosis behavior. Thus, it is possible that NO and cGMP, produced subsequent to activation of ␣ 1 -adrenoceptors in the HYP and POA, are key players in the temporal coordination of ovulation with the period of behavioral sexual receptivity.
It is also possible that NO and cGMP facilitate lordosis behavior in part by enhancing GnRH release. GnRH facilitates the display of lordosis behavior in estrogen-primed female rats (for review, see Pfaff et al., 1994) . GnRH neurons in the POA are surrounded by NO synthase-positive cells, although GnRH and NO synthase do not colocalize in the same cell (Bhat et al., 1995; Herbison et al., 1996) . The P receptor, which mediates cGMP effects on lordosis (Chu et al., 1999) , also mediates GnRH potentiation of lordosis (Beyer et al., 1997) . Together, one might speculate that the NOcGMP system is a convergent pathway for regulation of reproductive function by multiple neurotransmitters and hormones. NO, a small diffusible gas molecule and an important intercellular messenger, is especially suited to play such a coordinating role in the neuroendocrine control of reproduction.
The present study also demonstrates that both NE-stimulated cGMP production and the basal cGMP content in HYP-POA are derived predominantly from NO stimulation of soluble guanylyl cyclase. Cellular cGMP can come from two sources: the membrane-bound form of guanylyl cyclase and the soluble form of guanylyl cyclase. Guanylyl cyclase activity is considerably higher in the soluble than in the membrane fraction of most cell lysates (Garbers, 1989) . The ability of NO synthase inhibitors to abolish N E activation of cGM P synthesis and to drastically reduce basal cGM P levels indicates that NO-stimulated soluble guanylyl cyclase is the main enzyme responsible for both basal and agonist-induced cGM P synthesis in HYP-POA.
In conclusion, present results indicate that treatment of female rats with behaviorally effective doses of E 2 and P switches the preferred signaling pathways of ␣ 1 -adrenoceptors in the HYP-POA away from I P 3 formation and augmentation of adenylyl cyclase activity and to the production of NO -cGM P. Neither E 2 nor P alone is able to effect this change in ␣ 1 -adrenoceptor signal transduction. Moreover, combined administration of E 2 and P raises the basal activity of the NO -cGM P pathway even before any receptor stimulation. The lordosis data demonstrate that the link between ␣ 1 -adrenoceptors and the NO -cGM P pathway in the brain of EB plus P-treated animals is behaviorally relevant. Together, our data support the hypothesis that coupling of ␣ 1 -adrenoceptors to the NO -cGM P pathway is hormone-dependent and that this pathway mediates N E (i.e., ␣ 1 -adrenergic) facilitation of lordosis behavior in EB-and P-primed rats.
